Secondary forms of diabetes

Joslin's Diabetes Mellitus: Fourteenth Edition

Volumn , Issue , 2011, Pages 477-492

  Ganda, Om P ^a,b  

^a Joslin Clinic   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84970971268     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (214)

1. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1183-1197.
2. Seldin DW, Tarail R. Effect of hypertonic solutions on metabolism and excretion of electrolytes. Am J Physiol 1949;159:160-174.
3. Seltzer HS, Harris VL. Exhaustion of insulogenic reserve in maturity-onset diabetic patients during prolonged and continuous hyperglycemic stress. Diabetes 1964;13:6-13.
4. McCulloch DK, Koerker DJ, Kahn SE, et al. Correlations of in vivo D-cell function tests with D-cell mass and pancreatic insulin content in streptozocinadministered baboons. Diabetes 1991;40:673-679.
5. Kendall DM, Sutherland DER, Najarian JS, et al. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. . Engl J Med 1990;322:898-903.
6. Weir GC, Bonner-Weir S, Leahy JL. Islet mass and function in diabetes and transplantation. Diabetes 1990;39:401-405.
7. Barnes AJ, Bloom SR. Pancreatectomised man: a model for diabetes without glucagon. Lancet 1976;1:219-221.
8. Boden G. Extrapancreatic glucagon in human subjects. In: Unger RH, Orci L, eds. Glucagon: physiology, pathophysiology, and morphology of the pancreatic Acells. New York: Elsevier, 1981:349-357.
9. Tiengo A, Bessioud M, Valverde I, et al. Absence of islet alpha cell function in pancreatectomized patients. Diabetologia 1982;22:25-32.
10. Holst JJ, Pedersen JH, Baldissera F, et al. Circulating glucagon after total pancreatectomy in man. Diabetologia 1983;25:396-399.
11. Del Prato S, Tiengo A, Baccaglini U, et al. Effect of insulin replacement on intermediary metabolism in diabetes secondary to pancreatectomy. Diabetologia 1983;25:252-259.
12. Bajorunas DR, Fortner JG, Jaspan J, et al. Total pancreatectomy increases the metabolic response to glucagon in humans. . Clin Endocrinol Metab 1986;63:439-346.
13. de Kreutzenberg SV, Maifreni L, LiSato G, et al. Glucose turnover and recycling in diabetes secondary to total pancreatectomy: effect of glucagon infusion. . Clin Endocrinol Metab 1990;70:1023-1029.
14. Polonsky KS, Herold KC, Gilden JL, et al. Glucose counterregulation in patients after pancreatectomy: comparison with other clinical forms of diabetes. Diabetes 1984;33:1112-1119.
15. Barnes AJ, Bloom SR, Alberti KGMM, et al. Ketoacidosis in pancreatectomized man. . Engl J Med 1977;296:1250-1253.
16. Nosadini R, Del Prato S, Tiengo A, et al. Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. Diabetes 1982;31:346-355.
17. Yki-Järvinen H, Kiviluoto T, Taskinen M-R. Insulin resistance is a prominent feature of patients with pancreatogenic diabetes. Metabolism 1986;35:718-727.
18. Bajorunas DR, Dresler CM, Horowitz GD, et al. Basal glucagon replacement in chronic glucagon deficiency increases insulin resistance. Diabetes 1986;35:556-562.
19. Bank S. Chronic pancreatitis: clinical features and medical management. Am J Gastroenterol 1986;81:153-167.
20. Sjoberg, RJ, Kidd GS. Pancreatic diabetes mellitus. Diabetes Care 1989; 12:715-724.
21. Kalk WJ, Vinik AI, Jackson WPU, et al. Insulin secretion and pancreatic exocrine function in patients with chronic pancreatitis. Diabetologia 1979;16:355-358.
22. Andersen BN, Krarup T, Pedersen NT, et al. B cell function in patients with chronic pancreatitis and its relation to exocrine pancreatic function. Diabetologia 1982;23:86-89.
23. Donowitz M, Hendler R, Spiro HM, et al. Glucagon secretion in acute and chronic pancreatitis. Ann Intern Med 1975;83:778-781.
24. Persson I, Gyntelberg F, Heding LG, et al. Pancreatic-glucagon-like immunoreactivity after intravenous insulin in normals and chronic-pancreatitis patients. Acta Endocrinol 1971;67:401-404.
25. Larsen S, Hilsted J, Philipsen EK, et al. Glucose counter-regulation in diabetes secondary to chronic pancreatitis. Metabolism 1990;39:138-143.
26. Kalk WJ, Vinik AI, Paul M, et al. Immunoreactive glucagon responses to intravenous tolbutamide in chronic pancreatitis. Diabetes 1975;24:851-855.
27. Brunicardi FC, Chaiken RL, Ryan AS, et al. Pancreatic polypeptide administration improves abnormal glucose metabolism in patients with chronic pancreatitis. . Clin Endocrinol Metab 1996;81:3566-3572.
28. Williams JA, Goldfine ID. The insulin-pancreatic acinar axis. Diabetes 1985;34:980-986.
29. Baron JH, Nabarro JDN. Pancreatic exocrine function in maturity-onset diabetes mellitus. BMJ 1973;4:25-27.
30. Allen HF, Gay EC, Klingensmith GJ, et al. Identification and treatment of cystic fibrosis-related diabetes. A survey of current medical practice in the U.S. Diabetes Care 1998;21:943-948.
31. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999;45:61-73.
32. Moran A, Phillips J, Milla C. Insulin and glucose excursion following premeal insulin lispro or repaglinide in cystic fibrosis-related diabetes. Diabetes Care 2001;24:1706-1710.
33. Couce M, O'Brien TD, Moran A, et al. Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. . Clin Endocrinol Metab 1996;81:1267-1272.
34. Cohn JA, Jowell PS. Are mutations in the cystic fibrosis gene important in chronic pancreatitis? Surg Clin North Am 1999;79:723-731.
35. Sharer N, Schwarz M, Malone G, et al. Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. . Engl J Med 1998;339:645-652
36. Gullo L, Pezzilli R, Morselli-Labate AM. Diabetes and the risk of pancreatic cancer. Italian Pancreatic Cancer Study Group. . Engl J Med 1994;331: 81-84.
37. Everhart J, Wright D. Diabetes mellitus as a risk factor for pancreatic cancer. A meta-analysis. JAMA 1995;273:1605-1609.
38. Gapstur SM, Gann PH, Lowe W, et al. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000:283:2552-2558.
39. Permert J, Larsson J, Westermark GT, et al. Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. . Engl J Med 1994;330: 313-318.
40. Crosby WH. Hemochromatosis: current concepts and management. Hosp Pract 1987;22:173-192.
41. Andrews NC. Disorders of iron metabolism. . Engl J Med 1999;341:1986-1995.
42. Beutler E, Felitti V, Gelbart T, et al. The effect of HFE genotypes on measurements of iron overload in patients attending a health appraisal clinic. Ann Intern Med 2000;133:329-337.
43. Sanchez AM, Schreiber GB, Bethel J, et al. Prevalence, donation practices, and risk assessment of blood donors with hemochromatosis. JAMA 2001;286:1475-1481.
44. Steinberg KK, Cogswell ME, Chang JC, et al. Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. JAMA 2001;285:2216-2222.
45. Bulaj ZJ, Ajioka RS, Phillips JD, et al. Disease-related conditions in relatives of patients with hemochromatosis. . Engl J Med 2000;343:1529-1535.
46. Olynyk JK, Cullen DJ, Aquilia S, et al. A population-based study of the clinical expression of the hemochromatosis gene. . Engl J Med 1999;341:718-724.
47. Niederau C, Fischer R, Sonnenberg A, et al. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. . Engl J Med 1985;313:1256-1262.
48. Dymock IW, Cassar J, Pyke DA, et al. Observations on the pathogenesis, complications, and treatment of diabetes in 115 cases of haemochromatosis. Am J Med 1972;52:203-210.
49. Lassman MN, Genel M, Wise JK, et al. Carbohydrate homeostasis and pancreatic islet cell function in thalassemia. Ann Intern Med 1974;80:65-69.
50. Saudek CD, Hemm RM, Peterson CM. Abnormal glucose tolerance in D-thalassemia major. Metabolism 1977;26:43-52.
51. Conte D, Manachino D, Colli A, et al. Prevalence of genetic hemochromatosis in a cohort of Italian patients with diabetes mellitus. Ann Intern Med 1998;128:370-373.
52. Niederau C, Berger M, Stremmel W, et al. Hyperinsulinaemia in non-cirrhotic haemochromatosis: impaired hepatic insulin degradation? Diabetologia 1984;26:441-444.
53. Merkel PA, Simonson DC, Amiel SA, et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. . Engl J Med 1988;318:809-814.
54. Rahier JR, Loozen S, Goebbels RM, et al. The hemochromatotic human pancreas: a quantitative immunohistochemical and ultrastructural study. Diabetologia 1987;30:5-12.
55. Passa P, Luyckx AS, Carpentier JL, et al. Glucagon secretion in diabetic patients with idiopathic haemochromatosis. Diabetologia 1977;13:509-513.
56. Nelson RL, Baldus WD, Rubenstein AH, et al. Pancreatic -cell function in diabetic hemochromatotic subjects. . Clin Endocrinol Metab 1979;49:412-416.
57. Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among U.S. adults. Diabetes Care 1999:22:1978-1983.
58. O'Brien T, Bassett B, Burray DM, et al. Usefulness of biochemical screening of diabetic patients for hemochromatosis. Diabetes Care 1990;13:532-534.
59. Fernández-Real JM, Lopez-Bermejo A, Ricard W. Cross-talk between iron metabolism and diabetes. Diabetes 2002;51:2348-2354.
60. Schafer AI, Rabinowe S, LeBoff MS, et al. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Arch Intern Med 1985;145:1217-1221.
61. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, et al. Effect of age at the start of iron chelation therapy on gonadal function in D-thalassemia major. . Engl J Med 1990;323:713-719.
62. Young FG. The relation of the anterior pituitary gland to carbohydrate metabolism. BMJ 1939;2:393-396.
63. Fong HKW, Chick WL, Sato GH. Hormones and factors that stimulate growth of a rat islet tumor cell line in serum-free medium. Diabetes 1981;30:1022-1028.
64. Rabinovitch A, Quigley C, Rechler MW. Growth hormone stimulates islet B-cell replication in neonatal rat pancreatic monolayer cultures. Diabetes 1983;32:307-312.
65. Pierluissi J, Campbell J. Metasomatotrophic diabetes and its induction: basal insulin secretion and insulin release responses to glucose, glucagon, arginine and meals. Diabetologia 1980;18:223-228.
66. Daughaday WH. Growth hormone: normal synthesis, secretion, control and mechanisms of action. In: DeGroot LJ, Besser GM, Cahill GF Jr, et al, eds. Endocrinology, Vol 1, 2nd ed. Philadelphia: WB Saunders, 1989:318-329.
67. Press M. Growth hormone and metabolism. Diabetes Metab Rev 1988;4: 391-414.
68. Ganda OP, Simonson DS, Growth hormone, acromegaly and diabetes. Diabetes Rev 1993;1:2886-3000.
69. Arvat E, Maccario M, Di Vito L, et al. Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone. . Clin Endocrinol Metab 2001:86:1169-1174.
70. Hansen I, Taslikian E, Beaufrere B, et al. Insulin resistance in acromegaly: defects in both hepatic and extrahepatic insulin action. Am J Physiol 1986;250: E269-E273.
71. Metcalfe P, Johnston DG, Nosadini R, et al. Metabolic effects of acute and prolonged growth hormone excess in normal and insulin-deficient man. Diabetologia 1981;20:123-128.
72. Bratusch-Marrian PR, Smith D, DeFronzo RA. The effect of growth hormone on glucose metabolism and insulin secretion in man. . Clin Endocrinol Metab 1982;55:973-982.
73. Rizza RA, Mandarino LJ, Gerich JE. Effects of growth hormone on insulin action in man: mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. Diabetes 1982;31:663-669.
74. Zierler KL, Rabinowitz D. Roles of insulin and growth hormone, based on studies of forearm metabolism in man. Medicine (Baltimore) 1963;42: 385-402.
75. Fineberg SE, Merimee TJ. Acute metabolic effects of human growth hormone. Diabetes 1974;23:499-504.
76. Kahn CR, Goldfine ID, Neville DM Jr, et al. Alterations in insulin binding induced by changes in vivo in the levels of glucocorticoids and growth hormone. Endocrinology 1978;103:1054-1066.
77. Muggeo M, Saviolakis GA, Businaro V, et al. Insulin receptor on monocytes from patients with acromegaly and fasting hyperglycemia. . Clin Endocrinol Metab 1983;56:733-738.
78. Tai PK, Liao J-F, Chen EH, et al. Differential regulation of two glucose transporters by chronic growth hormone treatment of cultured 3T3-F442A adipose cells. . Biol Chem 1990;265:21828-21834.
79. Melmed S, Braunstein GD, Chang RJ, et al. Pituitary tumors secreting growth hormone and prolactin. Ann Intern Med 1986;105:238-253.
80. Jadresic A, Banks LM, Child DF, et al. The acromegaly syndrome: relation between clinical features, growth hormone values, and radiologic characteristics. . J Med 1982;202:189-204.
81. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf) 1987:26:481-512.
82. Molitch ME. Clinical manifestations of acromegaly. Endocrinol Metab Clin North Am 1992:21:597-614.
83. Ezzat S, Forster MJ, Berchtold P, et al. Acromegaly. Clinical and biochemical features in 500 patients. Medicine (Baltimore) 1994;73:233-240.
84. Sönksen PH, Greenwood FC, Ellis JP, et al. Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. . Clin Endocrinol Metab 1967;27:1418-1430.
85. Grinspoon S, Clemmons D, Swearingen B, et al. Serum insulin-like growth factor-binding protein-3 levels in the diagnosis of acromegaly. . Clin Endocrinol Metab 1995;80:927-932.
86. Gerich JE, Lorenzi M, Bier DM, et al. Effects of physiologic levels of glucagon and growth hormone on human carbohydrate and lipid metabolism: studies involving administration of exogenous hormone during suppression of endogenous hormone secretion with somatostatin. . Clin Invest 1976:57: 875-884.
87. Moller N, Schmitz O, Joorgensen JO, et al. Basal-and insulin-stimulated substrate metabolism in patients with active acromegaly before and after adenomectomy. . Clin Endocrinol Metab 1992;74:1012-1019.
88. Giustina A, Barkan A, Casanueva FF, et al. Criteria for cure of acromegaly: a consensus statement. . Clin Endocrinol Metab 2000;85:526-529.
89. Trainer PJ. Acromegaly-consensus, what consensus? . Clin Endocrinol Metab 2002;87:3534-3536.
90. Bates AS, Van't Hoff W, Jones JM, et al. An audit of outcome of treatment in acromegaly. . J Med 1993;86:293-299.
91. Rajasoorya C, Holdaway IM, Wrightson P, et al. Determinants of clinical outcome and survival in acromegaly. Clin Endocrinol (Oxf) 1994;41:95-102.
92. Colao A, Baldelli R, Marzullo P, et al. Systemic hypertension and impaired glucose tolerance are independently correlated to the severity of the acromegalic cardiomyopathy. . Clin Endocrinol Metab 2000;85:193-199.
93. Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. French SMS 201-995 approximately equal to Acromegaly Study Group. . Clin Endocrinol Metab 1990;71:391-397.
94. Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study. . Clin Endocrinol Metab 1995;80: 2768-2775.
95. Ho KK, Jenkins AB, Furler SM, et al. Impact of octreotide, a long-acting somatostatin analogue, on glucose tolerance and insulin sensitivity in acromegaly. Clin Endocrinol (Oxf) 1992;36:271-279.
96. Breidert M, Pinzer T, Wildbrett J, et al. Long-term effect of octreotide in acromegaly on insulin resistance. Horm Metab Res 1995;27:226-230.
97. Van der Lely AJ, Hutson RK, Trainer PJ, et al. Long-term treatment of acromegaly with pegvisomant, a growth-hormone receptor antagonist. Lancet 2001;358:1754-1759.
98. Daughaday WH, Kipnis DM. The growth-promoting and anti-insulin actions of somatotropin. Recent Prog Horm Res 1966;22:49-99.
99. Martin JM, Gagliardino JJ. Effect of growth hormone on the isolated pancreatic islets of rat in vitro. Nature 1967;213:630-631.
100. Merimee TJ, Fineberg SE, McKusick VA, et al. Diabetes mellitus and sexual ateliotic dwarfism: a comparative study. . Clin Invest 1970;49:1096-1102.
101. Merimee TJ. A follow-up study of vascular disease in growth-hormonedeficient dwarfs with diabetes. . Engl J Med 1978;298:1217-1222.
102. Thomas AM, Berglund L. Growth hormone and cardiovascular disease: an area in rapid growth. . Clin Endocrinol Metab 2001;86:1871-1873.
103. Colao A, Di Somma C, Cuocolo A, et al. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. . Clin Endocrinol Metab 2001;86:1874-1881.
104. Beshyah SA, Henderson A, Niththyananthan R, et al. The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. . Clin Endocrinol Metab 1995;80:356-363.
105. Rosenfalck AM, Maghsoudi S, Fisker S, et al. The effect of 30 months of lowdose replacement therapy with recombinant human growth hormone (rhGH) on insulin and C-peptide kinetics, insulin secretion, insulin sensitivity, glucose effectiveness, and body composition in GH-deficient adults. . Clin Endocrinol Metab 2000;85:4173-4181.
106. Koller EA, Green L, Gertner JM, et al. Retinal changes mimicking diabetic retinopathy in two nondiabetic, growth hormone-treated patients. . Clin Endocrinol Metab 1998;83:2380-2383.
107. Czernichow P, Albertsson-Wikland K, et al. Growth hormone treatment and diabetes: survey of the Kabi Pharmacia International Growth Study. Acta Paediatr Scand Suppl 1991;379:104-107.
108. Thornes MO. Critical evaluation of the safety of recombinant growth hormone administration: statement from the Growth Hormone Research Society. . Clin Endocrinol Metab 2001;86:1868-1870.
109. Katznelson L, Klibanski A. Prolactin and its disorders. In: Becker KL, ed. Principles and practice of endocrinology and metabolism, 3rd ed. New York: Lippincott Williams & Wilkins, 2001:145-153.
110. Landgraf R, Landgraf-Leurs MMC, Weissmann A, et al. Prolactin: a diabetogenic hormone. Diabetologia 1977;13:99-104.
111. Gustafson AB, Banasiak MF, Kalkhoff RK, et al. Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. . Clin Endocrinol Metab 1980;51:242-246.
112. Cahill GF Jr. Action of adrenal cortical steroids on carbohydrate metabolism. In: Christy NP, ed. The human adrenal cortex. New York: Harper and Row, 1971:205-238.
113. Exton JH, Miller TB Jr, Harper SC, et al. Carbohydrate metabolism in perfused livers of adrenalectomized and steroid-replaced rats. Am J Physiol 1976;230:163-170.
114. O'Brien RM, Lucas PC, Forest CD, et al. Identification of a sequence in the PEPCK gene that mediates a negative effect of insulin on transcription. Science 1990;249:533-537.
115. Olefsky JM. Effect of dexamethasone on insulin binding, glucose transport and glucose oxidation of isolated rat adipocytes. . Clin Invest 1975;56: 1499-1508.
116. Horner HC, Munck A, Lienhard GE. Dexamethasone causes translocation of glucose transporters from the plasma membrane to an intracellular site in human fibroblasts. . Biol Chem 1987;262:17696-17702.
117. Yasuda K, Hines E III, Kitabchi AE. Hypercortisolism and insulin resistance: comparative effects of prednisone, hydrocortisone, and dexamethasone on insulin binding of human erythrocytes. . Clin Endocrinol Metab 1982;55: 910-915.
118. Rebuffó-Scrive M, Krotkiewski M, et al. Muscle and adipose tissue morphology and metabolism in Cushing's syndrome. . Clin Endocrinol Metab 1988;67: 1122-1128.
119. Lambillotte C, Gilon P, Henquin JC. Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. . Clin Invest 1997;99:414-423.
120. Rizza RA, Mandarino LJ, Gerich JE. Cortisol-induced insulin resistance in man: impaired suppression of glucose production and stimulation of glucose utilization due to a postreceptor defect of insulin action. . Clin Endocrinol Metab 1982;54:131-138.
121. Shamoon H, Soman V, Sherwin RS. The influence of acute physiological increments of cortisol on fuel metabolism and insulin binding to monocytes in normal humans. . Clin Endocrinol Metab 1980;50:495-501.
122. Pupo AA, Wajchenberg BL, Schnaider J. Carbohydrate metabolism in hyperadrenocorticism. Diabetes 1966;15:24-29.
123. Boyle DJ. Cushing's disease, glucocorticoid excess, glucocorticoid deficiency, and diabetes. Diabetes Rev 1993;1:301-308.
124. Marco J, Calle C, Roman D, et al. Hyperglucagonism induced by glucocorticoid treatment in man. . Engl J Med 1973;288:128-131.
125. Wise JK, Hendler R, Felig P. Influence of glucocorticoids on glucagon secretion and plasma amino acid concentrations in man. . Clin Invest 1973;52: 2774-2782.
126. Cryer PE. Catecholamines, pheochromocytoma, and diabetes. Diabetes Rev 1993;1:309-317.
127. Landsberg L, Young JB. Catecholamines and the adrenal medulla. In: Wilson JD, Foster DW, eds. Williams textbook of endocrinology, 7th ed. Philadelphia: WB Saunders, 1985:891-965.
128. Robertson RP, Halter JB, Porte D Jr. A role for alpha-adrenergic receptors in abnormal insulin secretion in diabetes mellitus. . Clin Invest 1976;57:791-795.
129. Dunning BE, Taborsky GJ Jr. Galanin-sympathetic neurotransmitter in endocrine pancreas? Diabetes 1988;37:1157-1162.
130. Ortiz-Alonso FJ, Herman WH, Zobel DL, et al. Effect of epinephrine on pancreatic D-cell and -cell function in patients with NIDDM. Diabetes 1991;40: 1194-1202.
131. Strickland WG, Blackmore PF, Exton JH. The role of calcium in alphaadrenergic inactivation of glycogen synthase in rat hepatocytes and its inhibition by insulin. Diabetes 1980;29:617-622.
132. Garber AJ, Karl IE, Kipnis DM. Alanine and glutamine synthesis and release from skeletal muscle. IV. D-Adrenergic inhibition of amino acid release. . Biol Chem 1976;251:851-857.
133. Shamoon H, Jacob R, Sherwin RS. Epinephrine-induced hypoaminoacidemia in normal and diabetic human subjects: effect of beta blockade. Diabetes 1980; 29:875-881.
134. Stenström G, Sjöström L, Smith U. Diabetes mellitus in phaeochromocytoma: fasting blood glucose levels before and after surgery in 60 patients with phaeochromocytoma. Acta Endocrinol 1984;106:511-515.
135. Vance JE, Buchanan KD, O'Hara D, et al. Insulin and glucagon responses in subjects with pheochromocytoma: effect of alpha adrenergic blockade. . Clin Endocrinol Metab 1969;29:911-916.
136. Turnbull DM, Johnston DG, Alberti KGMM, et al. Hormonal and metabolic studies in a patient with a pheochromocytoma. . Clin Endocrinol Metab 1980; 51:930-933.
137. Hamaji M. Pancreatic -and D-cell function in pheochromocytoma. . Clin Endocrinol Metab 1979;49:322-325.
138. Bolli G, DeFeo P, Massi-Benedetti M, et al. Circulating catecholamine and glucagon responses to insulin-induced blood glucose decrement in a patient with pheochromocytoma. . Clin Endocrinol Metab 1982;54:447-449.
139. Conn JW. Hypertension, the potassium ion and impaired carbohydrate tolerance. . Engl J Med 1965;273:1135-1143.
140. Kotchen TA, Guthrie GP Jr. Renin-angiotensin-aldosterone and hypertension. Endocrinol Rev 1980;1:78-99.
141. Young WF Jr, Hogan MJ, Klee GG, et al. Primary aldosteronism: diagnosis and treatment. Mayo Clin Proc 1990;65:96-110.
142. Podolsky S, Melby JC. Improvement of growth-hormone response to stimulation in primary aldosteronism with correction of potassium deficiency. Metabolism 1976;25:1027-1032.
143. Sagild U, Andersen V, Andreasen PB. Glucose tolerance and insulin responsiveness in experimental potassium depletion. Acta Med Scand 1961;169:243-251.
144. Gorden P. Glucose intolerance with hypokalemia: failure of short-term potassium depletion in normal subjects to reproduce the glucose and insulin abnormalities of clinical hypokalemia. Diabetes 1973;22:544-551.
145. Loeb JN. Metabolic changes in thyrotoxicosis. In: Braverman LE, Utiger RD, Ingbar SH, Werner SC, eds. Werner and Ingbar's the thyroid: a fundamental and clinical text, 7th ed. Philadelphia: Lippincott Williams & Wilkins, 1996: 687-693.
146. Sandler MP, Robinson RP, Rabin D, et al. The effect of thyroid hormones on gluconeogenesis and forearm metabolism in man. . Clin Endocrinol Metab 1983;56:479-485.
147. Bratusch-Marrain PR, Komjati M, Waldhäusl WK. Glucose metabolism in noninsulin-dependent diabetic patients with experimental hyperthyroidism. . Clin Endocrinol Metab 1985;60:1063-1068.
148. Randin J-P, Tappy L, Scazziga B, et al. Insulin sensitivity and exogenous insulin clearance in Graves' disease: measurement by the glucose clamp technique and continuous indirect calorimetry. Diabetes 1986;35:178-181.
149. Shen D-C, Davidson MB, Kuo S-W, et al. Peripheral and hepatic insulin antagonism in hyperthyroidism. . Clin Endocrinol Metab 1988;66:565-569.
150. Foss MC, Paccola GMGF, Saad MJA, et al. Peripheral glucose metabolism in human hyperthyroidism. . Clin Endocrinol Metab 1990;70:1167-1172.
151. Maxon HR, Kreines KW, Goldsmith RE, et al. Long-term observations of glucose tolerance in thyrotoxic patients. Arch Intern Med 1975;135:1477-1480.
152. Beylot M, Riou JP, Bienvenu F, et al. Increased ketonaemia in hyperthyroidism: evidence for a D-adrenergic mechanism. Diabetologia 1980;19: 505-510.
153. Cooppan R, Kozak GP. Hyperthyroidism and diabetes mellitus: an analysis of 70 patients. Arch Intern Med 1980;140:370-373.
154. Kim H, Kalkhoff RK, Costrini NV, et al. Plasma insulin disturbances in primary hyperparathyroidism. . Clin Invest 1971;50:2596-2605.
155. Yasuda K, Hurukawa Y, Okuyama M, et al. Glucose tolerance and insulin secretion in patients with parathyroid disorders: effect of serum calcium on insulin release. . Engl J Med 1975;292:501-504.
156. Taylor WH, Khaleeli AA. Coincident diabetes mellitus and primary hyperparathyroidism. Diabetes Metab Res Rev 2001;17:175-180.
157. Harter HR, Santiago JV, Rutherford WE, et al. The relative roles of calcium, phosphorus, and parathyroid hormone in glucose-and tolbutamide-mediated insulin release. . Clin Invest 1976;58:359-367.
158. DeFronzo RA, Lang R. Hypophosphatemia and glucose intolerance: evidence for tissue insensitivity to insulin. . Engl J Med 1980;303:1259-1263.
159. Amend WJC Jr, Steinberg SM, Lowrie EG, et al. The influence of serum calcium and parathyroid hormone upon glucose metabolism in uremia. . Lab Clin Med 1975;86:435-444.
160. Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. . Engl J Med 1992;327:1919-1923.
161. Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med 1994;97:543-553.
162. Feigert JM, Sweet DL, Coleman M, et al. Multicentric angiofollicular lymph node hyperplasia with peripheral neuropathy, pseudotumor cerebri, IgA dysproteinemia, and thrombocytosis in women: a distinct syndrome. Ann Intern Med 1990;113:362-367.
163. Pandit MK, Burke J, Gustafson AB, et al. Drug-induced disorders of glucose tolerance. Ann Intern Med 1993;118:529-539.
164. Bengtsson C, Blohmó G, Lapidus L, et al. Do antihypertensive drugs precipitate diabetes? BMJ 1984;289:1495-1497.
165. Gurwitz JH, Bohn RL, Glynn RJ, et al. Antihypertensive drug therapy and the initiation of treatment for diabetes mellitus. Ann Intern Med 1993;118:273-278.
166. Grunfeld C, Chappell DA. Hypokalemia and diabetes mellitus [Editorial]. Am J Med 1983;75:553-554.
167. Trube G, Rorsman P, Ohno-Shosaku T. Opposite effects of tolbutamide and diazoxide on the ATP-dependent K+ channel in mouse pancreatic beta-cells. Pflugers Arch 1986;407:493-499.
168. Podolsky S, Pattavina CG. Hyperosmolar nonketotic diabetic coma: a complication of propranolol therapy. Metabolism 1973;22:685-693.
169. Burris JF. Beta-blockers, dyslipidemia, and coronary artery disease. A reassessment. Arch Intern Med 1993;153:2085-2092.
170. Pace CS, Livingston E. Ionic basis of phenytoin sodium inhibition of insulin secretion in pancreatic islets. Diabetes 1979;28:1077-1082.
171. Bouchard P, Sai P, Reach G, et al. Diabetes mellitus following pentamidineinduced hypoglycemia in humans. Diabetes 1982;31:40-45.
172. Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care 1995;18:47-55.
173. LeWitt PA. The neurotoxicity of the rat poison Vacor: a clinical study of 12 cases. . Engl J Med 1980;302:73-77.
174. Karam JH, Lewitt PA, Young CW, et al. Insulinopenic diabetes after rodenticide (Vacor) ingestion: a unique model of acquired diabetes in man. Diabetes 1980;29:971-978.
175. Kahn SE, Beard JC, Schwartz MW, et al. Increased D-cell secretory capacity as mechanism for islet adaptation to nicotinic acid-induced insulin resistance. Diabetes 1989;38:562-568.
176. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in noninsulin-dependent diabetes. JAMA 1990;264:723-726.
177. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000;284:1263-1270.
178. Teuscher AU, Seaquist ER, Robertson RP. Diminished insulin secretory reserve in diabetic pancreas transplant and nondiabetic kidney transplant recipients. Diabetes 1994;43:593-598.
179. Montori VM, Basu A, Erwin PJ, et al. Posttransplantation diabetes. A systematic review of the literature. Diabetes Care 2002;25:583-592.
180. Sumrani NB, Delaney V, Daskalakis P, et al. Retrospective analysis of posttransplantation diabetes mellitus in black renal allograft recipients. Diabetes Care 1991;14:760-762.
181. Kawai T, Shimada A, Kasuga A. FK506-induced autoimmune diabetes. Ann Intern Med 2000;132:511.
182. Feldman M, Kiser RS, Unger RH, et al. Beta-endorphin and the endocrine pancreas: studies in healthy and diabetic human beings. . Engl J Med 1983;308:349-353.
183. Giugliano D. Morphine, opioid peptides, and pancreatic islet function. Diabetes Care 1984;7:92-98.
184. Facchini F, Chen YD, Reaven GM. Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity. Diabetes Care 1994;17:115-119.
185. Kao WH, Puddey IB, Boland LL, et al. Alcohol consumption and the risk of type 2 diabetes mellitus: atherosclerosis in communities study. Am J Epidemiol 2001;154:748-775.
186. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-2099.
187. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000;160:2050-2056.
188. Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet 2001;357:592-598.
189. Hadigan C, Corcoran C, Basgoz N, et al. Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial. JAMA 2000;284: 472-477.
190. Walli R, Michl GM, Muhlbayer D, et al. Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Berl) 2000;199:253-262.
191. Henderson DC. Clozapine: diabetes mellitus, weight gain, and lipid abnormalities. . Clin Psychiatry 2001:62[Suppl 23]:39-44.
192. Goldstein LE, Henderson DC. Atypical antipsychotic agents and diabetes mellitus. Pry Psych 2001;7:65-68.
193. Koro CE, Fedder DO, L'Italian GJ, et al. Assessing of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ 2002;325: 243-247.
194. Lean MEJ, Pajonk FG. Patients on atypical antipsychotic drugs. Another high-risk group for type 2 diabetes. Diabetes Care 2003;26:1597-1605. 194a. ADA, APA, AACE, NAASD. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
195. Rotter JI, Vadheim CM, Rimoin DL. Genetics of diabetes mellitus. In: Rifkin H, Porte H, eds. Diabetes mellitus: theory and practice. New York: Elsevier, 1990: 378-413.
196. Bray GA, Dahms WT, Swerdloff, RS, et al. The Prader-Willi syndrome: a study of 40 patients and a review of the literature. Medicine (Baltimore) 1983; 62:59-80.
197. Green JS, Parfrey PS, Harnett JD, et al. The cardinal manifestations of Bardet-Biedl syndrome, a form of Laurence-Moon-Biedl syndrome. . Engl J Med 1989;321:1002-1009.
198. Katsanis N, Ansley SJ, Badano JL, et al. Triallelic inheritance in Bardet-Biedl syndrome, a Mendelian recessive disorder. Science 2001:293:2256-2259.
199. Schoenle EJ, Boltshauser EJ, Baekkeskov S, et al. Preclinical and manifest diabetes mellitus in young patients with Friedreich's ataxia: no evidence of immune process behind the islet cell destruction. Diabetologia 1989;32: 378-381.
200. Barrett TG, Bundey SE, Macleod AF. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995;346: 1458-1463.
201. Guillausseau PJ, Massin P, Dubois-LaForgue D, et al. Maternally inherited diabetes and deafness: a multicenter study. Ann Intern Med 2001;134 (9 Pt 1):721-728.
202. Karasik A, O'Hara C, Srikanta S, et al. Genetically programmed selective islet D-cell loss in diabetic subjects with Wolfram's syndrome. Diabetes Care 1989;12:135-138.
203. Kinsley BT, Swift M, Dumont RH, et al. Morbidity and mortality in the Wolfram syndrome. Diabetes Care 1995;18:1566-1570.
204. Leonard JV, Schapira AH. Mitochondrial respiratory chain disorders II: neurodegenerative disorders and nuclear gene defects. Lancet 2000;355: 389-394.
205. Tiengo A, Segato T, Briani C, et al. The presence of retinopathy in patients with secondary diabetes following pancreatectomy or chronic pancreatitis. Diabetes Care 1983;6:570-574.
206. Couet C, Genton P, Pointel JP, et al. The prevalence of retinopathy is similar in diabetes mellitus secondary to chronic pancreatitis with or without pancreatectomy and in idiopathic diabetes mellitus. Diabetes Care 1985;8: 323-328.
207. Feingold KR, Lee TH, Chung MY, et al. Muscle capillary basement membrane within patients with Vacor-induced diabetes mellitus. . Clin Invest 1986;78:102-107.
208. Passa P, Gauville C, Canivet J. Influence of muscular exercise on plasma levels of growth hormone in diabetics with and without retinopathy. Lancet 1974;2:72-74.
209. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors: studies in diabetes with or without retinopathy. . Engl J Med 1983;309:527-530.
210. Rymaszewski Z, Cohen RM, Chomczynski P. Human growth hormone stimulates proliferation of human retinal microvascular endothelial cells in vitro. Proc Natl Acad Sci U S A 1991;88:617-621.
211. Merimee TJ. A follow-up study of vascular disease in growth-hormonedeficient dwarfs with diabetes. . Engl J Med 1978;298:1217-1222.
212. Sharp PS, Fallon TJ, Brazier OJ, et al. Long-term follow-up of patients who underwent yttrium-90 pituitary implantation for treatment of proliferative diabetic retinopathy. Diabetologia 1987;30:199-207.
213. Passa P, Rousselie F, Gauville C, et al. Retinopathy and plasma growth hormone levels in idiopathic hemochromatosis with diabetes. Diabetes 1977;26:113-120.
214. Rabin D, Bloomgarden ZT, Feman SS, et al. Development of diabetic complications despite the absence of growth hormone in a patient with post-pancreatectomy diabetes. . Engl J Med 1984;310:837-839.